Chondrosarcoma is a bone cancer with an unusual problem: the standard tools of cancer medicine do not work on it. Chemotherapy largely fails. Radiation largely fails. Surgery with wide margins is the only treatment that reliably helps.
Researchers at Rowan University are taking a different approach to understanding why, using a 3D printer to build living models of the tumor's neighborhood. The two-year, $155,000 project is funded by the National Cancer Institute and led by Andrea Vernengo, an associate professor of chemical and biomedical engineering in Rowan's Henry M. Rowan College of Engineering, with co-principal investigator Tae Won B. Kim, an associate professor of orthopaedic surgery at Cooper Medical School of Rowan University and an orthopaedic oncologist at Cooper University Health Care and MD Anderson Cancer Center at Cooper.
This is early-stage laboratory research, funded to build a tool. The team is building a system to test a hypothesis, not reporting a treatment, and the central question has not yet been answered.
Why This Cancer Resists Standard Therapy
The biology behind the resistance explains why a better laboratory model is the bottleneck.
Chondrosarcoma arises from abnormal cartilage growth and is among the most common primary bone malignancies. Its defining feature is the dense extracellular matrix it deposits, rich in glycosaminoglycans and collagen.
That matrix is part of the problem. It is poorly vascularized, which limits how much of a systemically delivered drug reaches the tumor cells, and low oxygen conditions within it alter how cells respond to both chemotherapy and radiation. The cells also divide relatively slowly, and most conventional chemotherapy targets rapidly dividing cells.
The practical consequence for patients is that surgical margins carry enormous weight, since there is no effective systemic backup if cancer is left behind. When a tumor is in a location where wide resection is difficult, options narrow quickly.
The Hypothesis Involves Recruited Accomplices
The specific question the team is pursuing concerns cells that are not cancerous at all.
Chondrosarcoma cells release chemical signals that attract mesenchymal stem cells, the cells normally responsible for producing bone, cartilage, and other tissue. Those stem cells respond and migrate toward the tumor. The hypothesis is that they then change: instead of repairing and maintaining tissue as they normally would, they begin releasing cancer-promoting factors, including enzymes that break down tissue and make invasion easier.
"We believe this back-and-forth communication essentially turns the stem cells into accomplices that help out the tumor cells," Vernengo said, adding that understanding how it happens might reveal ways to interrupt the process and with it the growth of the tumor.
The team wants to confirm whether the chemical exchange actually transforms the stem cells' identity and, if so, how that shift unfolds over time. Neither has been established.
A Flat Dish Cannot Answer This Question
The reason the project needs a printer rather than a culture plate is specific, not a matter of preference.
Conventional cell culture grows cells flat on plastic in a single layer, and that arrangement discards most of what the researchers need to observe. It cannot represent distance, because every cell is essentially adjacent to every other. It cannot represent migration through tissue, because there is no tissue to migrate through. And it cannot represent the oxygen gradients and matrix density that define chondrosarcoma's environment.
The Rowan approach uses hydrogel, a soft biocompatible material, in samples roughly one square centimeter. A specialized 3D printer deposits cells within a stack of ringed channels inside the gel, placing tumor cells and stem cells in separate clusters at controlled distances from each other.
Controlling that distance is the whole experimental point. By adjusting the gel's temperature to loosen its texture, researchers can then permit the cells to migrate and observe whether they seek each other out, which Vernengo describes as a hallmark of cellular communication. The team plans to observe the interaction over 30 days, examining movement, metabolic activity and gene expression.
Two collaborators handle the molecular side. Sophia Orbach, an assistant professor of biomedical engineering, will examine RNA within individual cells to reconstruct how the stem cells' identity shifts over time. Susy Kohout, an associate professor of biomedical sciences at the medical school, will lead analysis of the molecular events driving the shift.
Vernengo originally developed the hydrogel technique to study how cartilage repairs itself. Kim, seeing the same tissue biology from the clinical side, suggested applying it to chondrosarcoma instead.
What This Means for Patients Today
The honest answer is nothing immediate, and that framing protects readers from false hope in a disease with few options.
There is no treatment here. There is no trial. Even if the hypothesis is confirmed, interrupting tumor and stem cell communication would require identifying the specific signals involved, finding a way to block them, demonstrating that blocking them slows tumors in animals, and then testing safety in people. That sequence typically spans many years.
What patients with chondrosarcoma can act on is surgical expertise. Because surgery is the treatment that determines outcome, evaluation at a center with high-volume orthopedic oncology experience is a reasonable step, and sarcoma care is generally concentrated in specialized centers for exactly this reason. Asking about margins, reconstruction options and the surgeon's volume in this specific tumor is appropriate.
Molecular testing of the tumor is worth discussing with an oncologist, since some chondrosarcomas carry IDH mutations and other alterations that may open clinical trial eligibility even where standard systemic therapy does not help.
Clinical trials for rare sarcomas are limited in number but do exist, and enrollment frequently requires travel to a specialized center. Sarcoma patient advocacy organizations maintain trial-matching resources.
Anyone with persistent deep bone pain, particularly pain that occurs at night or at rest, or a growing mass, should be evaluated rather than assuming an injury. This article is general information and is not a diagnosis.
Frequently Asked Questions
What is chondrosarcoma? A bone cancer arising from abnormal cartilage growth, and one of the most common primary bone malignancies.
Why is it hard to treat? It resists both chemotherapy and radiation, largely because of its dense, poorly vascularized matrix and slow cell division. Surgery is the main treatment.
What are the researchers doing? Using a 3D printer to place tumor cells and mesenchymal stem cells at controlled distances inside a hydrogel to study how they communicate over 30 days.
What is the hypothesis? That the tumor recruits stem cells and changes their behavior so they release factors that help the cancer invade surrounding tissue.
Why not use standard cell culture? Flat culture cannot represent distance, migration through tissue, or the oxygen and matrix conditions that define this tumor.
Is this a treatment? No. It is a two-year, $155,000 National Cancer Institute-funded laboratory project, and the central hypothesis has not been confirmed.
What should patients do? Seek evaluation at a center with high-volume sarcoma surgical experience and ask about molecular testing and trial options.
